Introduction
Cancer cells come under the in¯uence of important paracrine regulation from the host microenvironment (Cavenee, 1993) . Such host regulation may be as great a determinant of tumor cell behavior in vivo as the speci®c oncogenic or tumor suppressor alterations occurring within the malignant cells themselves, and may be mediated by speci®c extracellular matrix molecules, growth factors, or host cells (Liotta et al., 1991; Safarians et al., 1996) . Both positive (®broblast, and endothelial cell) and negative (tumor in®ltrating lymphocyte and macrophage) cellular regulators exist which profoundly aect tumor cell behavior in vivo (Folkman and Klagsbrun, 1987; Cornil et al., 1991) . One host cell, the myoepithelial cell, has escaped attention. The myoepithelial cell, which lies on the epithelial side of the basement membrane, contributes largely to the synthesis and remodeling of this structure. This cell lies in juxtaposition to normally proliferating and dierentiating epithelial cells in health and to abnormally proliferating and dierentiating epithelial cells in precancerous disease states such as ductal carcinoma in situ (DCIS) of the breast. This anatomical relationship suggests that myoepithelial cells may exert important paracrine eects on normal glandular epithelium and may negatively regulate the progression of DCIS to invasive breast cancer. Previous studies of our laboratory have demonstrated that the human myoepithelial cell exerts multiple tumor suppressive eects on breast carcinoma cells inhibiting both cellular invasion and proliferation as well as inducing apoptosis (Sternlicht et al., 1996a (Sternlicht et al., ,b, 1999 Shao et al., 1998) . The inhibition of invasion is mediated predominantly by myoepithelial maspin (Sternlicht et al., 1997; Shao et al., 1998) . In these previous studies (Sternlicht et al., 1996a (Sternlicht et al., ,b, 1997 Shao et al., 1998) , we used our established immortalized human myoepithelial cell lines and transplantable xenografts derived from benign or low grade human myoepitheliomas of the salivary gland, bronchus and breast. These cell lines and xenografts, though transformed, express nearly identical myoepithelial markers and gene products as their normal in situ counterparts and display an essentially normal diploid karyotype (Sternlicht et al., 1996b) . Furthermore they have maintained strong myoepithelial marker expression of S100 protein, smooth muscle actin, and cytokeratins over 100 passages. Unlike the vast majority of human tumor cell lines and xenografts which exhibit matrix-degrading properties these myoepithelial lines/xenografts like their normal myoepithelial counterparts in situ retain the ability to secrete and accumulate an abundant extracellular matrix composed of both basement membrane and nonbasement membrane components. When grown as monolayers these myoepithelial cell lines exert profound and speci®c eects on normal epithelial and primary carcinoma morphogenesis (Sternlicht et al., 1996b) . These studies support that our established myoepithelial lines/xenografts recapitulate a normal dierentiated myoepithelial phenotype and can therefore be used experimentally as a primary myoepithelial surrogate.
Because one other important cornerstone of tumor suppression would be a suppressive eect on angio-genesis and because the main product of the myoepithelial cell, the basement membrane, is thought to be a natural reservoir of angiogenic inhibitors (Folkman, 1990 (Folkman, , 1995b Weidner et al., 1991; Fridman et al., 1991) , we decided in the present study to investigate whether myoepithelial cells naturally display an anti-angiogenic phenotype. Because angiogenesis is now such an important biological phenomenon having implications in wound healing, in¯ammation and tumor biology, discovering and characterizing a new natural form of negative regulation of angiogenesis would have implications in all of these diverse areas of investigation.
Results
Myoepithelial cells in situ separate epithelial cells from stromal angiogenesis and this seemingly banal observation serves to illustrate the fact that stromal angiogenesis never penetrates this myoepithelial barrier ( Figure  1a ) raising the hypothesis that myoepithelial cells are natural suppressors of angiogenesis. This observation was re-inforced by a microscopic, immunohistochemical and DNA analysis of our myoepithelial xenografts. Our diverse myoepithelial xenografts secrete and accumulate an abundant extracellular matrix which is devoid of blood vessels in routine hematoxylin and eosin staining (Figure 1b ) and vWf immunocytochemical staining (Figure 1c ) in contrast to non-myoepithelial xenografts which show bursts of blood vessels (Figure 1d ). Quantitation of vessel density in 10 H.P.F.'s reveals absent to low vessel density in the myoepithelial xenografts compared to the non-myoepithelial xenografts (P50.01) (Figure 1e ). Murine DNA Cot-1 analysis further reveals the absence of a murine component in the myoepithelial xenografts. Since in the xenografts, angiogenesis would be murine in origin, the absence of a murine DNA component is another indication that angiogenesis is minimal. Interestingly the myoepithelial xenografts grew slowly compared to the non-myoepithelial xenografts ( Figure  1f ), a feature which was not found in comparisons between the myoepithelial versus non-myoepithelial cell lines (data not shown).
To explain these in vivo observations, we analysed the gene expression pro®les of our myoepithelial cell lines versus non-myoepithelial cell lines with respect to known angiogenic inhibitors and angiogenic factors. HMS-1, as a prototype myoepithelial cell line, constitutively expressed none or very low levels of the known angiogenic factors including bFGF, aFGF, angiogenin, TFGa, TGFb, TNF-a, VEGF, PD-ECGF, PlGF, IFa, HGF, and HB-EGF but rather expressed thrombospondin-1, TIMP-1 and soluble bFGF receptors at high levels; this was in contrast to a high angiogenic factor (which included bFGF, VEGF, TFGa, TGFb, HB-EGF, and PD-ECGF) to angiogenic inhibitor gene expression pro®le which was observed in non-myoepithelial cell lines (Figure 2a ). Other F Figure 1 (a) A layer of myoepithelial cells immunoreactive for maspin demarcates the separation of proliferating epithelial cells from underlying stroma in this case of DCIS. Angiogenesis which occurs in the stroma never penetrates this layer of myoepithelial cells. Human myoepithelial xenografts, for example, HMS-X (b) exhibit an abundant extracellular matrix devoid of blood vessels. Absent vWf immunoreactivity is depicted in HMS-4X (c) compared to strong vWf immunoreactivity in the non-myoepithelial xenograft, MDA-MB-231 (d). Density of vWf positive vessels in 10 H.P.F.'s of myoepithelial versus non-myoepithelial xenografts reveals absent to signi®cantly fewer blood vessels in the former xenografts (e). Growth rates of myoepithelial xenografts, for example, HMS-X, compared to growth rates of non-myoepithelial xenografts, for example, MDA-MB-231, revealed comparatively slow myoepithelial growth (f), suggesting a link to endogenously low levels of angiogenesis myoepithelial cell lines (HMS-2-6) exhibited an angiogenic inhibitor/angiogenic factor pro®le similar to that of HMS-1. Interestingly in 2 M urea extracts of the myoepithelial xenografts but not in any of the nonmyoepithelial xenografts, strong thrombospondin-1, TIMP-1 as well as plasminogen and prolactin fragments could be detected by Western blot (Figure 2a ). HMS-1 and HMS-1 CM (concentrated 10 ± 100-fold) exerted a marked inhibition of endothelial migration ( Figure 2b ) and proliferation (Figure 2c ), both of which were abolished by pretreatment of the myoepithelial cells with cyclohexamide or dexamethasone. HMS-1 cells themselves did not migrate in response to either K-SFM, FCS, or bFGF. When mixed with UVE, HMS-1 cells reduced endothelial migration to 12+6% of control (P50.01). HMS-1 concentrated CM reduced migration to 8+7% of control (P50.01). All of the non-myoepithelial malignant human cell lines studied stimulated both endothelial migration and proliferation. Concentrated CM from HMS-1, when fractionated on a heparin-Sepharose column, inhibited endothelial proliferation to 47+10% of control (P50.01). This inhibitory activity was present only in the 1.5 ± 2.0 M gradient fraction (Figure 2d ). Pretreatment of HMS-1 cells with PMA resulted in a 2 ± 5-fold increase in endothelial antiproliferative inhibitory activity in both unfractionated CM (Figure 2c the heparin-Sepharose column fractions revealed the presence of maspin in the load and wash fractions only and not in the 1.5 ± 2.0 M fraction; in contrast the 1.5 ± 2.0 M NaCl fraction contained thrombospondin-1 ( Figure 2d ). Immunoprecipitation of this fraction with anti-thrombospondin was eective at removing all thrombospondin-1 but decreased endothelial antiproliferative activity by only 50% raising the possibility that other angiogenic inhibitors as yet uncharacterized were present in this fraction. The other myoepithelial cell lines (HMS-2-6) exhibited similar anti-angiogenic inhibitory activity in their fractionated and unfractionated CM.
To further explain our in vivo observations of minimal angiogenesis in our myoepithelial xenografts, in vitro and in vivo hypoxia studies were carried out. Non-myoepithelial xenografts, e.g. MDA-MB-231 exhibited¯orid hypoxia but only minimal necrosis ( Figure 3a ) when they reached a size of 2.0 cm. In contrast, the myoepithelial xenografts exhibit only minimal hypoxia but prominent necrosis (P50.001) (Figure 3b, c) at the same size of 2.0 cm. Quantitation of the areas of hypoxia (pimonidazole immunoreactivity) and areas of necrosis ( Figure 3d ) in the myoepithelial versus non-myoepithelial xenografts suggest that in the myoepithelial tumors where angiogenesis is minimal hypoxic areas progress to necrosis rapidly whereas in the non-myoepithelial tumors hypoxic areas accumulate but do not progress to necrosis presumably from the angiogenesis which the hypoxia elicits. Comparative analysis of myoepithelial versus non-myoepithelial cell lines to low O 2 tension reveals that while both cell lines sense hypoxia in that they respond by increasing HIF-1a (Figure 3e ), the myoepithelial lines upregulate their steady state mRNA levels of the downstream genes, VEGF ( Figure 3f ) and iNOS ( Figure 3g ) to a lesser extent than the carcinoma lines suggesting the possibility of decreased transactivation of HRE. Speci®cally we observed an approximate 1.7-fold increase in VEGF (1.1-fold increase in iNOS) in myoepithelial cells in response to hypoxia compared to an approximate 2.5-fold increase in VEGF (1.5-fold increase in iNOS) in carcinoma cell lines in response to hypoxia. Although these fold dierences by themselves are not impressive, the absolute levels of VEGF (and iNOS) expressed in carcinoma cells in response to hypoxia are 2.5-fold greater for VEGF (and 1.7-fold greater for iNOS) than the levels of VEGF (and iNOS) expressed in myoepithelial cells in response to hypoxia. Therefore it can be concluded that myoepithelial cells do not express VEGF or iNOS in response to hypoxia to nearly the same extent as carcinoma cells.
To study both local and systemic eects of myoepithelial cells on metastasis, spontaneously metastasizing tumor cells were injected into our myoepithelial xenografts. The highly metastatic neoC8161 cells injected into the myoepithelial xenografts could be recovered in signi®cant numbers although the numbers of clones recovered were less than those recovered from the nonmyoepithelial xenografts. Histological analysis of the extirpated xenografts revealed neoC8161 cells actively invading through all of the nonmyoepithelial xenografts in contrast to the appearance within the myoepithelial xenografts where the neoC8161 cells were con®ned to the immediate areas around the injection site. Pulmonary metastases of neoC8161 were completely absent in the myoepithelial xenograft-injected group whereas they were quite numerous in the nonmyoepithelial group (P50.001). Analysis of extirpated myoepithelial xenografts containing injected neoC8161 cells contained no evidence of murine angiogenesis by either vWf immunocytochemical studies or murine DNA Cot-1 analysis whereas a similar analysis of extirpated neoC8161 injected-nonmyoepithelial xenografts showed an increase in murine angiogenesis by both methods (data not shown). This suggested that either the matrices of our myoepithelial xenografts or gene product(s) of the myoepithelial cells or both were inhibiting neoC8161-induced angiogenesis in vivo. We, in fact, found evidence of thrombospondin-1, TIMP-1, soluble bFGF receptors, prolactin and plasminogen fragments within 2 M urea extracts of our myoepithelial xenografts (Figure 4a ). In tail vein injection studies of neoC8161, in mice harboring the myoepithelial xenografts, neoC8161 formed smaller pulmonary colonies than in mice harboring nonmyoepithelial xenografts or in control mice (no xenografts) (P50.01) (Figure 4b, c, d) . In a vWf factor immunocytochemical analysis of these smaller colonies in the mice harboring the myoepithelial xenografts, angiogenesis was minimal (data not shown).
Discussion
Blood vessel proliferation (angiogenesis) occurs in a number of disease states including in¯ammation and neoplasia and both positive and negative regulators of angiogenesis exist that in¯uence this process. However angiogenesis is not ubiquitous and certain tissues such as mature cartilage are resistant to this process. Angiogenesis also does not occur on the epithelial side of the basement membrane even in proliferative and precancerous disease states which stimulate angiogeneis in the underlying stroma. The border between epithelial cells and stroma is lined by myoepithelial cells suggesting that these cells may exert negative regulation on the angiogenic process. Our studies, in fact, provide evidence that human myoepithelial cells are natural suppressors of angiogenesis and display this phenotype in a multifaceted manner.
Tumor angiogenesis, like tumor invasion, is thought to be determined by the balance of natural positive and negative regulators which occur within the tumor's microenvironment (Tobacman, 1997; Xiao et al., 1999; Folkman, 1995a; Hanahan and Folkman, 1996) . Although certain speci®c angiogenic inhibitors can be expressed by malignant cell lines, the vast majority of malignant cell lines secrete both more angiogenic factors than inhibitors and a greater molar ratio of angiogenic factors to inhibitors. Situations, both natural and therapeutic, which shift the overall balance to an excess of angiogenic inhibitors over angiogenic factors would be situations which are tumor suppressive. All of our myoepithelial cell lines constitutively expressed a high ratio of angiogenic inhibitors to angiogenic factors. The net eects of myoepithelial cells and their CM inhibited endothelial migration; in contrast the net eects of the non-myoepithelial malignant human cell lines studied all stimulated endothelial migration and proliferation. Heparin-Sepharose fractionated CM from our myoepithelial cell lines demonstrated a marked inhibition of endothelial proliferation in the 1.5 ± 2.0 M NaCl gradient fraction, a fraction containing thrombospondin-1 instead of maspin. Thrombospondin immunoprecipitation experiments performed on this fraction suggested that the mechanism of antiangiogenesis, in part, involved thrombospondin-1. It should be pointed out that our assays for antiangiogenic activity utilized human umbilical vein endothelial cells (commonly called HUVECs), cells which lack one of the receptors, CD36, to which thrombospondin-1 binds (Dawson et al., 1997) . However another study found proliferation in HUVECs to be inhibited by thrombospondin-1 (Bagavandoss and Wilkes, 1990) . The implication of these studies to our present work is that our use of HUVECs might have resulted in an underestimate of the thrombospondin-1 mediated antiangiogenic activity of CM from myoepithelial cell lines. Our use of microvascular endothelial cells might be more appropriate for our future studies. It is also interesting that in our human umbilical vein endothelial proliferation assays, maspin did not appear to have antiangiogenic activity. Maspin has recently been observed, in fact, to be an angiogenesis inhibitor (Zhang et al., 2000) . In that study, the antiangiogenic eects of maspin were observed against human microvascular endothelial cells and not human umbilical vein endothelial cells. Our previous studies have shown that myoepithelial cells secrete high levels of maspin both in vitro and in vivo (Sternlicht et al., 1997) . Myoepithelial maspin can hence be added to the growing list of angiogenic inhibitors produced selectively and at high levels by myoepithelial cells. Interestingly both maspin and thrombospondin-1 have been shown to be autocrine tumor suppressors in experiments involving their respective cDNAs transfected into breast carcinoma cell lines (Zou et al., 1994; Weinstat-Saslow et al., 1994) . In our past and present studies we argue for a role of both molecules as paracrine tumor suppressors elaborated by myoepithelial cells. The similarly enhancing eect of PMA on both invasion inhibition demonstrated in a previous study (Sternlicht et al., 1997) and angiogenesis inhibition demonstrated in the present study argues that PMA pleiotropically promotes the natural suppressor eects of myoepithelial cells.
There was minimal angiogenesis in our myoepithelial xenografts which also exhibited a very slow growth rate compared to their non-myoepithelial counterparts. This growth rate dierence was not observed between the myoepithelial versus nonmyoepithelial cell lines. It is attractive then to postulate that the slow growth of the myoepithelial xenografts is causally related to their minimal angiogenesis. To explain this minimal myoepithelial angiogenesis, we reasoned that there were three possible mechanisms. The ®rst was that myoepithelial cells expressed a balance of angiogenic inhibitors over angiogenic factors so that the myoepithelial tumor's microenvironment was inhibitory to angiogenesis. The second possible mechanism was that myoepithelial cells, like chondrocytes, either do not sense hypoxia or are resistant to the eects of hypoxia. The third possible mechanism was that myoepithelial cells experience hypoxia but are not able to respond to it by inducing angiogenesis. Our studies revealed that both the ®rst and third mechanisms are operating within myoepithelial cells but that the second mechanism is not: myoepithelial cells secrete a balance of angiogenic inhibitors over angiogenic factors, they do however sense hypoxia but are not able to respond eectively downstream to hypoxia. Figure 3 Pimonidazole immunoreactivity as a measure of hypoxia is prominently contrasted in a non-myoepithelial xenograft, the MDA-MB-231 (a), versus two myoepithelial xenografts, HMS-4X (b) and HMS-X (c). Only a thin rim of pimonidazole immunoreactivity (H) is present in the myoepithelial xenografts but instead large adjacent areas of frank necrosis (N) are conspicuous (b)(c). Necrosis (N) in the MDA-MB-231, in contrast, is inconspicuous but hypoxia (H) is prominent (a). Per cent hypoxia and per cent necrosis in the myoepithelial versus non-myoepithelial xenografts are contrasted (d). In the myoepithelial xenografts necrosis is prominent whereas hypoxia is inconspicuous where the reverse is true in the non-myoepithelial xenografts. Under low O 2 tension, myoepithelial cells, e.g. HMS-1 (HMS), like non-myoepithelial carcinoma cells, e.g., MDA-MB-231 (CA), show an increase in HIF-1a (e) but, unlike carcinoma cells (CA), show less of an increase in VEGF (f) and iNOS (g) steady state mRNA levels. Other myoepithelial and carcinoma lines tested exhibited a similar pattern of ®ndings versus non-myoepithelial xenografts (c) versus control (no xenografts). The number and size of metastatic colonies in midlongitudinal cross section of lung was determined by digital image analysis and expressed as mean+standard error. Quantitation of pulmonary metastases revealed similar numbers of colonies in all three groups but a marked decrease in size in the group harboring the myoepithelial xenografts (d). Results depict a representative myoepithelial xenograft, HMS-X, a representative nonmyoepithelial xenograft, MDA-MB-231, and control (no xenograft). Other myoepithelial and non-myoepithelial xenografts recapitulated these results processing within the matrices of HMS-X and HMS-4X to a novel 95 kDa fragment retaining full proteinase inhibitor activity and found bound to the myoepithelial matrix (Sternlicht et al., 1996a (Sternlicht et al., , 1997 . Interestingly when we screened myoepithelial cell CM by Western blots for angiogenic inhibitors, we did not observe evidence of plasminogen or prolactin secretion in the majority of our myoepithelial lines. However when we extracted our myoepithelial xenografts with 2 M urea we found evidence of processed fragments of plasminogen and prolactin in all of our myoepithelial xenografts. Whether these fragments represent angiogenic inhibitors (the 38 kDa angiostatin or the 16 kDa prolactin fragment) (O'Reilly et al., 1994; Clapp et al., 1993) remains to be determined. Since most of our myoepithelial cell lines do not secrete the parental molecules in vitro, the fragments are likely derived from circulating murine parental molecules which are sequestered by the anionic myopithelial matrix and processed. There are therefore two types of molecules present within the myoepithelial matrix, molecules secreted by the myoepithelial cells themselves, e.g. thrombospondin-1 and TIMP-1 and molecules sequestered from the circulation, e.g. prolactin and plasminogen and processed. These latter molecules perhaps serve as substrates for unknown enzymes produced by myoepithelial cells. Certain other cell types such as small cell carcinoma can sequester within their stroma, for example, circulating antithrombin and subsequently cleave this molecule to produce a conformationally altered molecule which has antiangiogenic activity (O'Reilly et al., 1999) . Myoepithelial cells with their abundant and anionically charged stroma may similarly sequester and process circulating molecules into highly antiangiogenic forms.
G
Highly metastatic neoC8161 cells when injected into the matrices of our myoepithelial xenografts predictably then were not able to stimulate angiogenesis nor metastasize. Since viable neoC8161 cells could still be recovered from the xenografts, it likely is the bound angiogenic inhibitors, e.g. thrombospondin-1 and TIMP-1 and possibly the processed fragments of the parental plasminogen and prolactin originally derived from the circulation that are responsible for the local anti-angiogenic eects. Our myoepithelial xenografts were also able to suppress distant pulmonary metastases after hematogenous dissemination of tumor cells following intravenous injection. It is attractive to postulate that this systemic eect on metastasis inhibition is mediated through the release rather than the sequestration of angiogenic inhibitors. One implication then of our in vivo ®ndings is that myoepithelial xenografts give rise to circulating inhibitors of angiogenesis. Another possibility to explain our observations is that our myoepithelial xenografts sequester and remove circulating angiogenic factors from serum. Both phenomenon would be anti-angiogenic. We are presently screening serum and urine for antiangiogenic activity and have observed in preliminary studies inhibition of endothelial proliferation in vitro with both serum and concentrated urine from mice harboring myoepithelial xenografts. We will be attempting to purify this angiogenic inhibitory activity in the near future.
Past studies have shown that dierent human and murine cell lines and xenografts produce dierent angiogenic inhibitors (O'Reilly et al., 1994 (O'Reilly et al., , 1997 (O'Reilly et al., , 1999 . Myoepithelial cell lines and xenografts exhibit unique anti-angiogenic properties, suggesting that they may represent a natural source of angiogenic inhibitors yet undiscovered.
Materials and methods

Cell lines and xenografts
Informed patient consent and certi®cation from the UCLA Human Subject Protection Committee was obtained. Approval from the Chancellor's Animal Research Committee was also requested and obtained (certi®cation ARC 95-127-11). Early passage (passage 10 ± 15) human myoepithelial cell lines/xenografts: HMS-1-6, X-6X established in our laboratory (Sternlicht et al., 1996a (Sternlicht et al., ,b, 1997 Shao et al., 1998) were used. Other non-myoepithelial cell lines/xenografts used included the human melanomas, C8161 (Dr Mary Hendrix, University of Iowa) and M15 (Dr Don Morton, John Wayne Cancer Center, Santa Monica, CA, USA); the human breast carcinomas, MDA-MB-231, MDA-MB-468, MCF-7, T47D, BT-549, MDA-MB-157, Hs578T, Hs578Bst; other malignant lines including the A431, vulvar carcinoma, A253, salivary gland carcinoma and HT-29, colon carcinoma (American Type Culture Collection, Rockville, MD, USA). The highly metastatic C8161 line was transfected by us with pSV2neo in a previous study (Safarians et al., 1996) . Normal cells used included human mammary epithelial cells (HMEC) and human umbilical vein endothelial cells (UVE) (Clonetics, San Diego, CA, USA). Serum free conditioned media (CM) was collected from many of these lines over 24 h and concentrated 10 ± 100-fold using Centriprep-10 concentrators (Amicon, Beverly, MA, USA). Prior to collection of CM, myoepithelial cells were also pretreated with: cyclohexamide (CHX) (40 mg/ml) for 24 h; phorbol 12-myristate 13-acetate (PMA) (5 mM) for 8 h; dexamethasone (0.25 mM) for 24 h. The growth of the dierent myoepithelial xenografts was observed in 4 week old female athymic/scid mice and compared to the growth of non-myoepithelial xenografts.
Antibodies and probes
High molecular weight genomic DNA was extracted from the myoepithelial and non-myoepithelial xenografts and dot blotted and probed with a murine speci®c a-32 P-dCTP-labeled murine Cot-1 DNA probe (Life Technologies, Inc., Gaithersburg, MD, USA) to determine the murine DNA component of the xenografts (Alpaugh et al., 1999) .
Angiogenic factors, angiogenic inhibitors and other relevant molecules were pro®led by Western blot analysis of concentrated CM of the cell lines and 2 M urea extracts of the xenografts according to established methods (Sternlicht et al., 1996a (Sternlicht et al., , 1997 . Western blots were performed as previously described using the manufacturers' recommended dilutions for primary antibodies and a 1 : 50 000 dilution of horseradish peroxidase-conjugated goat anti-mouse as secondary antibody (Amersham Life Sciences, Arlington Heights, IL, USA) followed by development of the reaction with the ECL detection system (Amersham Life Sciences, Arlington Heights, IL, USA). Primary rabbit polyclonal antibodies to maspin were obtained (PharMingen, San Diego, CA, USA). Primary antibodies to known angiogenic factors and angiogenic inhibitors included mouse monoclonals or rabbit polyclonals to bFGF, aFGF, angiogenin, TFGa, TGFb, TNF-a, VEGF, PD-ECGF, PlGF, IFa, HGF, HB-ECGF and IF-a (all from R&D Systems, Minneapolis, MN, USA); plasminogen and PF4 (American Diagnostica, Inc., Greenwich, CT, USA); thrombospondin-1 (Sigma Bio Sciences, St. Louis, MO, USA); rabbit anti-rTIMP-1, (Dr Judith C Gasson, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA); prolactin (Dr Richard Weiner, University of California, San Francisco, CA, USA); and bFGF soluble receptor (Dr Anne Hanneken, Scripps Research Institute, LaJolla, CA, USA). Relative levels of expression of the angiogenic factors and angiogenic inhibitors were expressed as`pie slices'. The pie slices refer to the semiquantitative (relative) levels of expression of a given factor in dierent (myoepithelial versus non-myoepithelial) cell lines. Because of diering anities of primary antibodies, the size of the pie slices can not be compared among factors. Scion Image software was used for densitometric analyses of the bands and quanti®cation of the signal on Western blots developed by ECL. Also used was a primary rabbit antibody to identify endothelial cells (blood vessels): anti-von Willebrand factor (vWf) (DAKO, Carpinteria, CA, USA). Standardized immunoprecipitation protocols using Sepharose-protein A (Langone, 1982) were employed in the evaluation of thrombospondin-1 activities.
Formalin-®xed paran-embedded tissues of human myoepithelial and non-myoepithelial xenografts at a size (1.0 cm diameter) where necrosis was minimal were incubated with rabbit antibodies to vWf (1 : 1000). Peroxidase-conjugated goat anti-rabbit IgG was used as secondary antibody at 1/200 dilution. Colorimetric detection of peroxidase-conjugated secondary antibody was with diaminobenzidine. The number of vWf pro®les per high power ®eld (H.P.F.) in 10 high power ®elds (H.P.F.'s) from each xenograft was determined.
In vitro angiogenic chemotaxis and proliferation assays
Standard endothelial migration assays were carried out over 4 h using a chemotaxis chamber (Neuroprobe, Cabin John, MD, USA) with 10 ng/ml bFGF as chemoattractant (Nguyen et al., 1993) . Eects of HMS-1-6 CM (concentrated 10 ± 100-fold) and HMS-1-6 cells added to the upper compartment were tested. Standard endothelial proliferation assays (O'Reilly et al., 1997) were also carried out over 72 h with 25 mg/ml endothelial mitogen (Biomedical Technologies, Stoughton, MA, USA). Heparin-Sepharose NaCl gradient fractionated HMS-1-6 CM was analysed for inhibitory activity.
In vitro hypoxia studies
To establish an hypoxic environment (Namiki et al., 1995) , cells were placed in a Modular Incubator Chamber (BillupsRothenberg, Inc., Del Mar, CA, USA), and a pre-analysed air mixture (1% O 2 , 5% C0 2 , and 94% N 2 ) was¯ushed through the air-tight chamber for 15 min twice a day. The chamber was then placed in a 378C incubator, and hypoxia was maintained for 6 ± 24 h. After an initial 6 h period of hypoxia, the cells were harvested and their nuclear fraction collected as follows: Cells were harvested and thawed on ice and reconstituted in 5 volumes of buer A (10 mM Tris, pH 7.5, 1.5 mM MgCl 2 , 10 mM KCl) with freshly added supplements (1 M DTT, 0.2 M PMSF, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 0.5 M Na 3 VO 4 ). The suspension was then passed through a pre-cooled homogenizer using 25 strokes to lyse the cells. The lysate was then centrifuged for 10 min at 48C, and the supernatant collected and stored as the cytoplasmic fraction. The pellet was then resuspended in 3.5 volumes of buer C (0.42 M KCl, 20 mM Tris, pH 7.5, 1.5 mM MgCl 2 , 20% glycerol) with the same supplements as above freshly added. The suspension was then centrifuged for 30 min at 48C, and the supernatant was collected as the nuclear fraction. Western blot analysis on this nuclear fraction for HIF-1a was performed using a monoclonal antibody to HIF-1a (Lab Vision Corporation, Fremont, CA, USA). After a 24 h period of hypoxia, the cells were harvested, total RNA extracted and 20 mg separated on denaturing agarose gels, transferred to nylon membranes, and probed with a-32 P-dCTP-labeled probes using standard Northern blot protocols. cDNA probes used included VEGF (Dr Howard Reber, UCLA) and iNOS (Dr Gautam Chaudhuri, UCLA). The 36P4 probe (Dr Judith Berliner, UCLA) was used as a housekeeping probe.
In vivo hypoxia studies
The principle that pimonidazole binds to thiol-containing proteins speci®cally in hypoxic cells (Varia et al., 1998) was exploited by immunocytochemical detection of pimonidazole using a mouse monoclonal antibody (Dr James Raleigh, UNC, Chapel Hill, NC, USA) in tissue sections of the myoepithelial versus the non-myoepithelial xenografts grown in mice receiving intraperitoneal injections of pimonidazole hydrochloride (0.5 g/m 2 ) followed by extirpation of the xenografts 24 h later and immunocytochemical analysis. Pimonidazole immunoreactivity was present as cytoplasmic staining. The number of hypoxic cells (positively stained) was expressed as a percentage of total. Areas showing frank necrosis were also observed and quantitated. Care was taken in these comparative studies to use xenografts of equal size; for these studies xenografts measuring 2.0 cm in diameter were used.
In vivo angiogenesis and metastasis studies
The myoepithelial xenografts (HMS-X, HMS-3X and HMS-4X) and non-myoepithelial xenografts (MDA-MB-231, MDA-MB-468) were established in nude and scid mice and allowed to grow to a size of 1.0 cm. This size was chosen because there was no appreciable necrosis in any of the xenografts at this size. 10 5 neoC8161 cells suspended in 50l Hank's Balanced Salt Solution (HBSS) were injected into the centers of the xenografts and allowed to grow for 4 ± 8 weeks. Random xenografts from each group were injected with 50l trypan blue instead of cells and immediately extirpated to verify that the injections had been delivered to the centers of the xenografts. After 4 ± 8 weeks, animals were sacri®ced and primary tumors and lungs were subjected to detailed histopathological examination, collagenase digestion, and culturing of the liberated cells in G418 sulfate (0.2 mg/ml) (Life Technologies, Inc., Gaithersburg, MD, USA). The number of recovered neoC8161 clones from each site was determined by phase-contrast image analysis of the cultured dishes. The extirpated xenografts were also studied immunocytochemically for evidence of vWf immunoreactivity and subjected to DNA extraction and murine DNA Cot-1 analysis to estimate the degree of murine angiogenesis. 10 ebrand factor; PMA, phorbol 12-myristate 13-acetate; bFGF, basic ®broblast growth factor; aFGF, acidic ®broblast growth factor; TFGa, transforming growth factor a; TGFb, transforming growth factor b; TNFa, tumor necrosis factor a; VEGF, vascular endothelial growth factor; PD-ECGF, platelet-derived endothelial cell growth factor; PlGF, placental growth factor; IFa, interferon a; HGF, hepatocyte growth factor; HB-EGF, heparin-binding endothelial growth factor; PF4, platelet factor 4; and iNOS, inducible nitric oxide synthase; HIF1a, hypoxia inducible factor-1a; HRE, hypoxia response element.
